PRGO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRGO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Perrigo Co is: High Risk: High uncertainty with risk-return tradeoff.
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Perrigo Co's Risk Assessment falls into.
Perrigo Co (NYSE:PRGO) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Perrigo Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Willis | officer: Acting CHRO | C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010 |
Alison Ives | officer: EVP & Chief Scientific Officer | C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010 |
Eduardo Guarita Bezerra | officer: EVP & Chief Financial Officer | C/O FRESH DEL MONTE PRODUCE INC., PO BOX 149222, CORAL GABLES FL 33134 |
Patrick Lockwood-taylor | director, officer: CEO | C/O PERRIGO COMPANY PLC, 430 MONROE AVE NW, GRAND RAPIDS MI 49503 |
Julia M Brown | director | C/O ABLE BRANDS CO., 30 HUDSON YARDS, NEW YORK NY 10001 |
Triona Schmelter | officer: EVP & President CSCA | 2021 SPRING ROAD, SUITE 600, OAK BROOK IL 60523 |
Geoffrey M. Parker | director | 15 RIORDAN PLACE, MENLO PARK CA 94025 |
Svend Andersen | director | C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010 |
Murray S Kessler | director, officer: CEO | 714 GREEN VALLEY ROAD, GREENSBORO NC 27408 |
Thomas Farrington | officer: Senior VP and CIO | 4012 W. CANTERBURY CT., NEQUON WI 53092 |
Dillard James E Iii | officer: EVP, Chief Scientific Officer | 6601 WEST BROAD STREET, RICHMOND VA 23230 |
Ronald Craig Janish | officer: EVP, Global Op. & Supply Chain | PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010 |
Grainne Quinn | officer: EVP, Chief Medical Officer | PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010 |
Albert Manzone | director | C/O MERISANT, AVENUE JEAN-JACQUES ROUSSEAU 7, NEUCHATEL V8 CH-2000 |
Kyle Hanson | officer: EVP & General Counsel |
From GuruFocus
By GuruFocus Research • 11-07-2023
By PRNewswire PRNewswire • 03-28-2023
By GuruFocus Research • 11-15-2023
By PRNewswire PRNewswire • 02-28-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 05-04-2023
By PRNewswire • 07-13-2023
By PRNewswire PRNewswire • 05-10-2023
By PRNewswire • 08-24-2023
By GuruFocus Research • 05-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.